Candriam Equities L Biotechnology Class R GBP Cap

Performance History31/01/2020
Growth of 1,000 (GBP) Advanced Graph
Candriam Equities L Biotechnology Class R GBP Cap
Fund-3.516.6-5.030.8-4.8
+/-Cat0.56.33.010.6-2.0
+/-B’mrk2.75.5-1.810.50.4
 
Key Stats
NAV
18/02/2020
 GBP 272.72
Day Change -0.26%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN LU1269736911
Fund Size (Mil)
18/02/2020
 USD 1707.51
Share Class Size (Mil)
18/02/2020
 GBP 0.25
Max Initial Charge 3.50%
Ongoing Charge
13/12/2019
  1.07%
Morningstar Research
Analyst Report

Candriam Equities Biotechnology benefits from an experienced and talented lead manager and has a well-structured and thorough process in place, but the firm’s decision to drastically increase the maximum capacity of the strategy to accommodate...

Click here to read this analyst report on the underlying fund.
Morningstar Pillars
PeoplePositive
ParentNeutral
ProcessPositive
PerformancePositive
PriceNegative
Investment Objective: Candriam Equities L Biotechnology Class R GBP Cap
The objective of the sub-fund is to benefit from the performance of the market in global equities of companies in the biotechnology sector, on the basis of discretionary management.
Returns
Trailing Returns (GBP)18/02/2020
YTD2.85
3 Years Annualised10.57
5 Years Annualised*8.86
10 Years Annualised*18.85
12 Month Yield 0.00
Management
Manager Name
Start Date
Rudi Van den Eynde
06/04/2000
Servaas Michielssens
01/01/2019
Inception Date
08/03/2016
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDNASDAQ Biotechnology TR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNo
OtherNot Specific
Portfolio Profile for  Candriam Equities L Biotechnology Class R GBP Cap31/12/2019
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock94.320.0094.32
Bond0.000.000.00
Property0.000.000.00
Cash6.360.675.68
Other0.000.000.00
Top 5 Regions%
United States90.56
Eurozone3.67
Europe - ex Euro2.68
United Kingdom0.94
Asia - Emerging0.92
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Vertex Pharmaceuticals IncHealthcareHealthcare7.83
Gilead Sciences IncHealthcareHealthcare6.76
Amgen IncHealthcareHealthcare6.70
Regeneron Pharmaceuticals IncHealthcareHealthcare6.11
Biogen IncHealthcareHealthcare5.11
Candriam Equities L Biotechnology Class R GBP Cap
* This share class has performance data calculated prior to the inception date, 2016-03-08. This is based upon a simulated/extended track record, using the track record of Candriam Eqs L Biotech C USD Cap (ISIN: LU0108459040), and is in accordance with Morningstar’s Extended Performance Methodology paper. To find out more about this, click here.
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites